Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 7(109), p. 1782-1785, 2013

DOI: 10.1038/bjc.2013.527

Links

Tools

Export citation

Search in Google Scholar

The interaction between prognostic and pharmacodynamic biomarkers

Journal article published in 2013 by L. Bouranis, M. Sperrin, Alastair Greystoke ORCID, Caroline Dive, Andrew G. Renehan
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background:Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Methods:Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy.Results:The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker.Conclusion:These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions.British Journal of Cancer advance online publication, 3 September 2013; doi:10.1038/bjc.2013.527 www.bjcancer.com. ; Bouranis, L Sperrin, M Greystoke, A Dive, C Renehan, A G Br J Cancer. 2013 Sep 3. doi: 10.1038/bjc.2013.527.